5. TRPV1 and Inflammatory Pain

  1. Arthur Gomtsyan and
  2. Connie R. Faltynek
  1. Anindya Bhattacharya1,
  2. Sonya G. Lehto2 and
  3. Narender R. Gavva3

Published Online: 22 FEB 2010

DOI: 10.1002/9780470588284.ch5

Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

How to Cite

Bhattacharya, A., Lehto, S. G. and Gavva, N. R. (2010) TRPV1 and Inflammatory Pain, in Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders (eds A. Gomtsyan and C. R. Faltynek), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470588284.ch5

Editor Information

  1. Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA

Author Information

  1. 1

    Department of Pain and Related Disorders, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA

  2. 2

    Department of Neuroscience Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA

  3. 3

    Department of Neuroscience Amgen Inc., Thousand Oaks, CA, USA

Publication History

  1. Published Online: 22 FEB 2010
  2. Published Print: 12 FEB 2010

ISBN Information

Print ISBN: 9780470175576

Online ISBN: 9780470588284

SEARCH

Keywords:

  • role for TRPV1 in pain states and inflammatory pain;
  • activation mechanisms of TRPV1 during inflammation;
  • maximal efficacy of TRPV1 antagonists and end-point measurements in inflammatory pain models

Summary

This chapter contains sections titled:

  • Introduction

  • Expression of TRPV1 during Inflammation

  • TRPV1 Mediates Inflammatory Pain

  • Activation Mechanisms of TRPV1 during Inflammation

  • Efficacy of TRPV1 Antagonists in the CFA Model of Inflammatory Pain

  • Efficacy of TRPV1 Antagonists in the Carrageenan Model of Inflammatory Pain

  • Efficacy of TRPV1 Antagonists in the Formalin Model of Inflammatory Pain

  • TRPV1 Antagonists can be Divided into Distinct Groups

  • Critical Features of Antagonists Required for Efficacy in Pain Models

  • Perspectives

  • References